Psilocybin and other psychedelics are forcing their way out of prohibition as potentially viable treatments for not only depression and anxiety but also Alzheimer’s and other neurodegenerative diseases plaguing millions in North America alone. In the end, psilocybin solutions address a $300 billion dollar psychotherapy and wellness global market.
Equity Guru’s own Ethan Reyes spoke with Nikita Alexandrov, CTO of ThinkMyco to get a good look at the company, the sector and what lies ahead for investors.
Listen in!
